Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

COVID-19 Resources »      Vaccine Update »      Visitor Policy »

Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (MPNs)

Myeloproliferative disorders are a group of rare illnesses that cause blood cells in the bone marrow, including red blood cells, white blood cells, and platelets, to grow and develop abnormally.

Myeloproliferative disorders occur when the body produces too many of one or more types of blood cells. However, the reason for this remains unknown. Researchers believe that genetics and/or the environment may play a role in the development of these disorders.

Myeloproliferative disorders are serious medical conditions. Complications of these disorders may be fatal. A person's survival rate depends on the type of myeloproliferative disorder he/she has, as well as the severity of his/her illness.

Although there is no cure for myeloproliferative disorders, treatment may help patients live several years after they are diagnosed.

INTERESTED IN AN ONLINE SECOND OPINION?

The Stanford Medicine Online Second Opinion program offers you easy access to our world-class doctors. It’s all done remotely and you don’t have to visit our hospital or one of our clinics for this service. You don’t even need to leave home!

Visit our online second opinion page to learn more.

Clinical Trials for Myeloproliferative Neoplasms

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Clinics for Myeloproliferative Neoplasms